Alvimopan

FDA Approved: * December 19, 2019
Pharm Company: * WATSON LABS TEVA
Category: Gastrointestinal

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Alvimopan Overview

Alvimopan (trade name Entereg) is a drug which behaves as a peripherally acting μ-opioid receptor antagonist. With the limited ability to cross the blood–brain barrier and reach the μ-opioid receptors of the central nervous system, the clinically undesirable effects of centrally acting opioid antagonists (like reversal of opioid-mediated analgesia) are avoided without affecting the intended blockade of μ-opioid receptors in the gastrointestinal tract.[1]&a...

Read more Alvimopan Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Alvimopan

Recent Alvimopan Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Alvimopan: (1 result)

Sorted by National Drug Code

• 0591-2312 Alvimopan 12 mg Oral Capsule by Actavis Pharma, Inc.

Other drugs which contain Alvimopan or a similar ingredient: (1 result)

• ENTEREG Alvimopan